Increased osteoprotegerin levels in Cushing's syndrome are associated with an adverse cardiovascular risk profile

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 5, 2007, Pages 1803-1808

  Dovio, Andrea ^a   Allasino, Barbara ^a   Palmas, Enrico ^a   Ventura, Massimo ^a   Pia, Anna ^c   Saba, Laura ^a   Aroasio, Emiliano ^b   Terzolo, Massimo ^a   Angeli, Alberto ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

^c S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; HYDROCORTISONE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; UNCLASSIFIED DRUG;

ADENOMA; ADRENAL GLAND; ADRENAL HYPERPLASIA; ADULT; AGED; ARTICLE; BLOOD LEVEL; BONE DENSITY; CANCER STAGING; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY RISK; CORRELATION ANALYSIS; CUSHING SYNDROME; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE RELEASE; HUMAN; HYPOPHYSIS; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION; BLOOD; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; ENDOCRINE FUNCTION TEST; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RADIODENSITOMETRY; RISK;

ADRENAL GLANDS; ADRENOCORTICOTROPIC HORMONE; ADULT; AGED; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; CUSHING SYNDROME; DENSITOMETRY, X-RAY; FEMALE; HUMANS; HYDROCORTISONE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OSTEOPROTEGERIN; PITUITARY FUNCTION TESTS; PITUITARY GLAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RISK;

EID: 34249861442     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-2283     Document Type: Article

References (36)

1. Hofbauer LC, Schoppet M 2004 Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292:490-495
2. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D 2004 The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 15:457-475
3. Rogers A, Eastell R 2005 Circulating osteoprotegerin and receptor activator for nuclear factor κB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90:6323-6331
4. Dovio A, Data V, Angeli A 2005 Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice? J Endocrinol Invest 28(10 Suppl):14-22
5. Collin-Osdoby P 2004 Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 95:1046-1057
6. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, Schwartz SM, Giachelli CM, Rosenfeld ME 2006 Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 26:2117-2124
7. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M 2003 Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593-5602
8. Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A 2006 Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 17:144-149
9. Dovio A, Sartori ML, Masera RG, Ceoloni B, Reimondo G, Prolo P, Racca S, Angeli A 2003 Autocrine down-regulation of glucocorticoid receptors by interleukin-11 in human osteoblast-like cell lines. J Endocrinol 177:109-117
10. Sasaki N, Kusano E, Ando Y, Nemoto J, Iimura O, Ito C, Takeda S, Yano K, Tsuda E, Asano Y 2002 Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. Bone 30:853-858
11. von Tirpitz C, Epp S, Klaus J, Mason R, Hawa G, Brinskelle-Schmal N, Hofbauer LC, Adler G, Kratzer W, Reinshagen M 2003 Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. Eur J Gastroenterol Hepatol 15:1165-1170
12. Valleala H, Mandelin J, Laasonen L, Koivula MK, Risteli J, Konttinen YT 2003 Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. Eur J Endocrinol 148:527-530
13. Ueland T, Bollerslev J, Godang K, Muller F, Froland SS, Aukrust P 2001 Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess - possible role in bone homeostasis. Eur J Endocrinol 145:685-690
14. Reimondo G, Allasino B, Bovio S, Paccotti P, Angeli A, Terzolo M 2005 Evaluation of the effectiveness of midnight serum cortisol in the diagnostic procedures for Cushing's syndrome. Eur J Endocrinol 153:803-809
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 2001 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497
16. http://www.sisalombardia.it/; last access 06.09.06
17. Guidelines Committee European Society of Hypertension-European Society of Cardiology 2003 Guidelines for the management of arterial hypertension. J Hypertens 21:1011-1053
18. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 1997 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197
19. Browner WS, Lui LY, Cummings SR 2001 Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86:631-637
20. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J 2004 Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109:2175-2180
21. Pivonello R, Faggiano AG, Lombardi G, Colao A 2005 The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am 34:327-339
22. Hurwitz Eller N, Netterstrom B, Hansen AM 2001 Cortisol in urine and saliva: relations to the intima media thickness, IMT. Atherosclerosis 159:175-185
23. Terzolo M, Pia A, Ali A, Osella G, Reimondo G, Bovio S, Daffara F, Procopio M, Paccotti P, Borretta G, Angeli A 2002 Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 87:998-1003
24. Maddali KK, Korzick DH, Turk JR, Bowles DK 2005 Isoform-specific modulation of coronary artery PKC by glucocorticoids. Vascul Pharmacol 42:153-162
25. Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS, Noonan H, Nunes CN, Olson SH, Pikounis B, Ren N, Robertson N, Schaeffer JM, Shah K, Springer MS, Strack AM, Strowski M, Wu K, Wu T, Xiao J, Zhang BB, Wright SD, Thieringer R 2005 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 202:517-527
26. Morand EF, Leech M, Bernhagen J 2006 MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 5:399-410
27. Onodera S, Sasaki S, Ohshima S, Amizuka N, Li M, Udagawa N, Irie K, Nishihira J, Koyama Y, Shiraishi A, Tohyama H, Yasuda K 2006 Transgenic mice overexpressing macrophage migration inhibitory factor (MIF) exhibit high-turnover osteoporosis. J Bone Miner Res 21:876-885
28. Giustina A, Veldhuis JD 1998 Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717-797
29. Ueland T 2004 Bone metabolism in relation to alterations in systemic growth hormone. Growth Horm IGF Res 14:404-417
30. Olesen P, Ledet T, Rasmussen LM 2005 Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-α. Diabetologia 48:561-568
31. Indridason OS, Franzson L, Sigurdsson G 2005 Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int 16:417-423
32. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y 1999 Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 14:518-527
33. Khosla S, Arrighi HM, Melton 3rd LJ, Atkinson EJ, O'Fallon WM, Dunstan C, Riggs BL 2002 Correlates of osteoprotegerin levels in women and men. Osteoporos Int 13:394-399
34. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD 2001 Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 86:3162-3165
35. Minetto M, Reimondo G, Osella G, Ventura M, Angeli A, Terzolo M 2004 Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome. Osteoporos Int 15:855-861
36. Ohmori N, Nomura K, Ohmori K, Kato Y, Itoh T, Takano K 2003 Osteoporosis is more prevalent in adrenal than in pituitary Cushing's syndrome. Endocr J 50:1-7